Alternatives to RBC Transfusion:

Transcription

1 Alternatives to RBC Transfusion: beyond Erythropoietin and David Shimabukuro, MDCM Department of Anesthesia and Perioperative Care Medical Director, 13 ICU UC SF 1

2 Agenda Background Erythropoietin Hemoglobin-based oxygen carrier (HBOC) Perfluorocarbon emulsion UC SF 2

3 Background Infection RISKS BENEFITS UC SF 3

4 Background Infection RISKS BENEFITS UC SF 4

5 Background Infection RISKS BENEFITS UC SF 5

6 Agenda Background Erythropoietin Hemoglobin-based oxygen carrier (HBOC) Perfluorocarbon emulsion UC SF 6

7 Erythropoietin Stimulates bone marrow to produce red blood cells Elevated in anemia Blunted levels in critically ill Interleukin-1 Tumor necrosis factor Anemia of critical illness UC SF 7

8 Erythropoietin Corwin and colleagues Prospective, randomized, double-blind, placebo-controlled, multicenter trial Assess weekly dosing of recombinant human erythropoietin (rhuepo) of 40,000 units to decrease occurrence of RBC transfusion (transfusion independence) Corwin, et al. JAMA 288;22: UC SF 8

9 Erythropoietin 1302 patients 650 rhuepo and 652 placebo Received SQ injection on ICU day 3 Study days 1, 7, and 14 Held if HCT > 37% Exclusion Renal Failure on dialysis Acute ischemic heart disease Acute GI bleeding UC SF 9

10 Erythropoietin Transfusion protocol No RBC transfusion if Hgb > 90 g/l, unless clinically indicated For Hgb < 90 g/l, transfusion at the discretion of the physician UC SF 10

11 Erythropoietin Baseline Hemoglobin (g/dl) Total number placebo Total number rhuepo < Mean pretransfusion Hgb 8.5 g/dl UC SF 11

12 Erythropoietin Placebo rhuepo Total number of units transfused Units transfused per patient: Mean Units transfused per patient: Median UC SF 12

13 Erythropoietin Conclusion Weekly administration of rhuepo reduces allogeneic RBC transfusion and increases hemoglobin Addresses only RBC transfusion and not powered for mortality or significant adverse events Transfusion decided by individual physicians UC SF 13

14 Erythropoietin Corwin and colleagues (NEJM Sept 6 07) Efficacy and Safety of Epoetin Alfa in Critically Ill Patients Multicenter, prospective, randomized, placebo-controlled trial ( ) UC SF 14

15 Erythropoietin Primary Endpoint: percentage of patients receiving RBC transfusion between study days 1 and 29 Secondary Endpoints: number of RBC units transfused between days 1 and 42, mortality at day 29 and 140 UC SF 15

16 Erythropoietin Inclusion Criteria Age > 18 Hgb < 12 g/dl At least 2 days in ICU Exclusion Critieria Acute ischemic heart disease during ICU stay History of DVT, PE, or ischemic stroke Dialysis Uncontrolled hypertension UC SF 16

17 Erythropoietin UC SF 17

18 Erythropoietin Epoetin Alfa 40,000 units or placebo was given SQ on study day 1 and weekly for a total of 3 doses (days 1, 8, and 15) Study drug withheld from patients with Hgb > 12 g/dl (for second and third doses) All patients received PO iron on day 1 or when able to take PO UC SF 18

19 Erythropoietin RBC transfusion determined by physician Target Hgb: 7-9 g/dl Transfusion not recommended if Hgb > 9 g/dl or Hct > 27 unless specific clinical indication (active bleeding or ischemia) No Hgb level of Hct concentration for which transfusion was mandated UC SF 19

20 Erythropoietin Baseline characteristics same between study drug and placebo groups However Surgical patients and medical patients were older than trauma patients (mean 64 vs 60 vs 41) Surgical patients and medical patients had more one or more coexisiting diseases (89% vs 89% vs 32%) UC SF 20

21 Erythropoietin UC SF 21

22 Erythropoietin UC SF 22

23 Erythropoietin UC SF 23

24 Erythropoietin UC SF 24

25 Erythropoietin Conclusions: No difference in percentage of patients receiving RBC transfusions between the Epoetin Alfa and placebo groups Decrease in 29-day and 140-day mortality for trauma patients who receive Epoetin Alfa versus placebo and may be beneficial Non-trauma surgical and medical patients should not receive Epoetin Alfa, unless there is an approved indication UC SF 25

26 Erythropoietin However Significant increase in thrombotic complications in the Epoetin Alfa group over the placebo group UC SF 26

27 Hemoglobin-based Oxygen Carriers UC SF 27

28 Hemoglobin-based Oxygen Carriers Oxyhemoglobin Saturation (%) RBC Hemoglobin Hemoglobin-based Oxygen Carrier Stroma Free Hemoglobin PaO2 (mmhg) UC SF 28

29 Hemoglobin-based Oxygen Carriers Cross-linked Hb (intramolecular) Polymerized Hb (intermolecular) Conjugated Hb UC SF 29

30 Hemoglobin-based Oxygen Carriers Cross-linked Hb Napolitano Crit Care Clin 25 (2009) UC SF 30

31 Hemoglobin-based Oxygen Carriers Polymerized Hb Napolitano Crit Care Clin 25 (2009) UC SF 31

32 Hemoglobin-based Oxygen Carriers Conjugated Hb Napolitano Crit Care Clin 25 (2009) UC SF 32

33 Hemoglobin-based Oxygen Carriers Renal Failure Precipitation in tubules Systemic and Pulmonary Hypertension NO scavenging UC SF 33

34 Hemoglobin-based Oxygen Carriers Resolution of initial problems with second and third generation HBOC Some still with issues, others in phase II and phase III clinical trials UC SF 34

35 Hemoglobin-based Oxygen Carriers Class Product Company Technology Status Cross-linked HemAssist (DCL) Baxter Cross-linked Discontinued US Army Cross-linked Discontinued rhb 1.1 Somatogen rhb Discontinued rhb 2.0 Baxter rhb Discontinued Polymerized PolyHeme Northfield Laboratories Gluteraldehyde, pyridoxal Hb HemoPure Biopure Glutaraldehyde bovine Hb Phase III Phase III HemoLink Hemosol Polymerized Discontinued Conjugated PHP Apex Bioscience PEG-human Hb Phase III PEG-Hb Enzon PEG-bovine Hb Discontinued MalPEG-Hb Sangart PEG-human Hb Phase III UC SF 35

36 Hemoglobin-based Oxygen Carriers Characteristic HemoPure PolyHeme MP4 RBC Volume (ml) Hb concentration (g/dl) P 50 (mmhg) Oncotic pressure (mmhg) Viscosity (cp) (WB) Methemoglobin (%) <15 <8 <10 <1 Half-life 19 hours 24 hours 24 hours 30 days Shelf life at 4 C 3 years 1.5 years >1 year 42 days Refrigeration No No No Yes UC SF 36

37 Hemoglobin-based Oxygen Carriers Still requires Hb Vasoactivity Gastrointestinal side effects Interference with laboratory results UC SF 37

38 UC SF 38

39 Perfluorocarbon Emulsion UC SF 39

40 Oxygent : Perfluorocarbon Emulsion Lecithin stabilization Cleared very quickly by reticuloendothelial system (<6H) and exhaled unchanged Perflubron (perfluoroocytl bromide) UC SF 40

41 Perfluorocarbon Emulsion O2 Content (ml/100ml) PFC 2.4 g/dl PFC 1.6 g/dl Plasma Dissolved O 2 PaO2 (mmhg) UC SF 41

42 Perfluorocarbon Emulsion Requires high FIO2 to achieve higher oxygen content Increase in plasma cytokines (flu-like symptoms) Short half-life Long shelf life Easy to manufacture UC SF 42

43 Standl Infus Ther Transfus Med 2000;27: UC SF 43

44 Summary Few alternatives available to PRBC transfusion to increase arterial oxygen content Erythropoietin is not recommended for most situations of anemia of critical illness UC SF 44

45 Summary Hemoglobin-based oxygen carriers are still in testing and development, along with perfluorocarbons There are even still other ideas UC SF 45